Literature DB >> 12148596

Serum sFAS levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases.

Marta Christensson1, Erna Pettersson, Kjell Eneslätt, Birger Christensson, Johan Bratt, Solbritt Rantapää-Dahlqvist, Karl-Gösta Sundqvist.   

Abstract

The role of the Fas/FasL system in ANCA-associated vasculitis is unclear. We therefore assessed levels of soluble Fas (sFas) in sera and Fas expression on mononuclear cells from patients with ANCA-positive vasculitis and compared the results with those found in other rheumatic diseases. Serum levels of sFas were determined by ELISA. The ANCA-positive vasculitis patients studied included 29 at onset, 17 in first remission while on therapy, and 12 in quiescence. For comparison, 10 patients with Sjogren's syndrome (SS), 14 patients with systemic lupus erythematosus (SLE), 29 patients with rheumatoid arthritis (RA), 7 patients on dialysis (DP), and 26 healthy controls (HC) were studied. In addition, Fas expression in mononuclear cells was examined at the mRNA level using reverse transcriptase (RT)-PCR in 6 vasculitis patients at onset and in first remission. The expression of CD95 on the surface of leukocytes was determined by flow cytometry in 6 vasculitis patients at onset of the disease, in 6 patients in clinical remission, and in 6 HC. Expression of Fas and FasL in renal biopsy specimens was studied using immunohistochemistry. Patients with vasculitis had high sFas levels irrespective of disease phase. Both vasculitis patients and patients with RA and SLE had significantly increased sFas levels compared with healthy controls. All patient groups had sFas levels, which correlated with raised serum creatinine values. However, the sFas levels in vasculitis patients in first remission and in quiescence were increased despite a lower serum creatinine compared with onset. Some of the vasculitis patients showed an increased mRNA expression of Fas in mononuclear cells after treatment, suggesting that Fas production fluctuates with the intensity of the disease. The expression of CD95 on leukocytes was slightly decreased in vasculitis patients compared to healthy controls. No alterations of Fas and FasL expression were seen in renal biopsy specimens. These results show that ANCA-positive vasculitis patients have high sFas levels and that the levels remain elevated even in clinical remission. The findings indicate that perturbations in the Fas/Fas ligand system may play a role in the disease process in ANCA vasculitis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12148596     DOI: 10.1023/a:1016040925295

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  30 in total

Review 1.  Fas ligand, death gene.

Authors:  M J Pinkoski; D R Green
Journal:  Cell Death Differ       Date:  1999-12       Impact factor: 15.828

2.  Increased expression of functional Fas-ligand in activated T cells from patients with systemic lupus erythematosus.

Authors:  B Kovacs; S N Liossis; G J Dennis; G C Tsokos
Journal:  Autoimmunity       Date:  1997       Impact factor: 2.815

3.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

4.  Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases.

Authors:  S Jodo; S Kobayashi; N Kayagaki; N Ogura; Y Feng; Y Amasaki; A Fujisaku; M Azuma; H Yagita; K Okumura; T Koike
Journal:  Clin Exp Immunol       Date:  1997-01       Impact factor: 4.330

5.  Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community.

Authors:  C Vitali; S Bombardieri; H M Moutsopoulos; G Balestrieri; W Bencivelli; R M Bernstein; K B Bjerrum; S Braga; J Coll; S de Vita
Journal:  Arthritis Rheum       Date:  1993-03

6.  Increase in CD95 (Fas/APO-1)-positive CD4+ and CD8+ T cells in peripheral blood derived from patients with autoimmune hepatitis or chronic hepatitis C with autoimmune phenomena.

Authors:  S Ogawa; K Sakaguchi; A Takaki; K Shiraga; T Sawayama; H Mouri; M Miyashita; N Koide; T Tsuji
Journal:  J Gastroenterol Hepatol       Date:  2000-01       Impact factor: 4.029

Review 7.  The role of Fas and related death receptors in autoimmune and other disease states.

Authors:  R M Siegel; T A Fleisher
Journal:  J Allergy Clin Immunol       Date:  1999-05       Impact factor: 10.793

8.  Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis.

Authors:  E Knipping; P H Krammer; K B Onel; T J Lehman; E Mysler; K B Elkon
Journal:  Arthritis Rheum       Date:  1995-12

Review 9.  Vasculitis-susceptible genes in mice with a deficit in Fas-mediated apoptosis.

Authors:  M Nose; M Terada; M Nishihara; J Kamogawa; T Miyazaki; S Mori; M Nishimura; Y Wang; T Kamoto; H Hiai
Journal:  Int J Cardiol       Date:  1998-10-01       Impact factor: 4.164

10.  Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

Authors:  R A Luqmani; P A Bacon; R J Moots; B A Janssen; A Pall; P Emery; C Savage; D Adu
Journal:  QJM       Date:  1994-11
View more
  6 in total

1.  Elevated levels of soluble Fas (APO-1, CD95), soluble Fas ligand, and matrix metalloproteinase-3 in sera from patients with active untreated adult onset Still's disease.

Authors:  Der-Yuan Chen; Joung-Liang Lan; Fang-Ju Lin; Tsu-Yi Hsieh
Journal:  Clin Rheumatol       Date:  2006-09-14       Impact factor: 2.980

2.  Dendritic cells overexpressing Fas-ligand induce pulmonary vasculitis in mice.

Authors:  S Buonocore; V Flamand; N Claessen; P Heeringa; M Goldman; S Florquin
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

3.  Role of soluble Fas ligand in autoimmune diseases.

Authors:  Ning-Li Li; Hong Nie; Qi-Wen Yu; Ji-Ying Zhang; An-Lun Ma; Bai-Hua Shen; Li Wang; Jun Bai; Xue-Hua Chen; Tong Zhou; Dong-Qing Zhang
Journal:  World J Gastroenterol       Date:  2004-11-01       Impact factor: 5.742

4.  The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis.

Authors:  Aşkin Ateş; Gülay Kinikli; Murat Turgay; Murat Duman
Journal:  Clin Rheumatol       Date:  2004-05-15       Impact factor: 2.980

5.  Decreased neutrophil apoptosis in quiescent ANCA-associated systemic vasculitis.

Authors:  Mohamed Abdgawad; Åsa Pettersson; Lena Gunnarsson; Anders A Bengtsson; Pierre Geborek; Lars Nilsson; Mårten Segelmark; Thomas Hellmark
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

6.  Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus.

Authors:  Fabien B Vincent; Rangi Kandane-Rathnayake; Rachel Koelmeyer; James Harris; Alberta Y Hoi; Fabienne Mackay; Eric F Morand
Journal:  Lupus Sci Med       Date:  2020-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.